EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseÜbersichtsarbeit

Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials

Daniel Isufi iD, Niloufar Javanmardi, Mikkel Bak Jensen iD, Nikolai Loft iD, Lone Skov iD, Jesper Elberling, Simon Francis Thomsen iD, Farzad Alinaghi iD

International Journal of Dermatology · 2026-04 · 65 (4) · 737-745

DOI: 10.1111/ijd.70122 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Dermatology, online erschienen am 29.10.2025. Verfasst von Daniel Isufi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Dyslipidemias, Janus Kinase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors (JAKi) have sparked a new era in the treatment of immune‐mediated diseases. While some studies have reported an increased incidence of dyslipidemia in JAKi‐treated patients, the full extent of this adverse event is not established. The study aimed to assess the association between treatment with oral JAKi and dyslipidemia in phases 2 and 3 placebo‐controlled randomized clinical trials (RCTs). A systematic review and meta‐analysis were conducted, encompassing phase 2 and 3 RCTs. The Embase, PubMed, and Web of Science databases were searched up to March 9, 2025. Only RCTs reporting lipid levels before and after treatment with JAKi were included. Data were extracted for changes in high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), total cholesterol (TC), and triglycerides (TG) with values reported in mg/dL. A total of 13 studies were included in the analysis, comprising nine studies on rheumatoid arthritis, two on atopic dermatitis, one on Crohn's disease, and one on psoriasis. The studies encompassed a total of 3978 patients treated with JAKi and 1680 controls. Across all indications, the mean difference between JAKi and placebo for individual drug, was increased by 6.07 mg/dL (95% confidence interval [CI], 5.01–7.14) for HDL and 9.05 mg/dL (95% CI, 7.78–10.32) for LDL for baricitinib; HDL 5.4 mg/dL (95% CI, 3.2–7.7) and LDL 12.4 mg/dL (95% CI, 8.9–15.9) for upadacitinib; HDL 7.0 mg/dL (95% CI, 5.7–8.3) and LDL 15.7 mg/dL (95% CI, 12.9–18.6) for tofacitinib; and lastly HDL 3.0 mg/dL (95% CI, 0.2–5.8) and LDL 14.9 mg/dL (95% CI, 3.6–26.3) for decernotinib. This systematic review and meta‐analysis highlight the risk of dyslipidemia during treatment with JAKi, which could pose cardiovascular risks. Thus, regular assessments of cardiovascular risk factors and routine lipid monitoring in patients undergoing JAKi therapy may be essential for managing dyslipidemia and evaluating long‐term cardiovascular safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasJanus Kinase InhibitorsHumansRandomized Controlled Trials as TopicPsoriasisAdministration, OralArthritis, RheumatoidCrohn DiseasePyrimidinesClinical Trials, Phase II as TopicSulfonamidesAzetidinesPiperidinesPurinesPyrazoles

Stichwörter der Autor:innen

JAK inhibitorsJanus kinase inhibitordyslipidemiaimmune‐mediated diseasesmeta‐analysisrandomized clinical trials

Substanzen

Janus Kinase InhibitorstofacitinibPyrimidinesbaricitinibSulfonamidesAzetidinesPiperidinesPurinesPyrazoles

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
  • National Allergy Research Centre, Department of Dermatology and Allergy, University of Copenhagen, Hellerup, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Dermato-Venereology & Wound Healing Centre, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Daniel Isufi, Mikkel Bak Jensen, Nikolai Loft, Lone Skov, Simon Francis Thomsen, Farzad Alinaghi

Zitieren

APA

Isufi, D., Javanmardi, N., Jensen, M. B., Loft, N., Skov, L., Elberling, J., Thomsen, S. F., & Alinaghi, F. (2026). Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials. International Journal of Dermatology, 65(4), 737-745. https://doi.org/10.1111/ijd.70122

Vancouver

Isufi D, Javanmardi N, Jensen MB, Loft N, Skov L, Elberling J, et al. Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials. International Journal of Dermatology. 2026;65(4):737-745. doi:10.1111/ijd.70122

BibTeX
@article{Isufi2026,
  author = {Isufi, Daniel and Javanmardi, Niloufar and Jensen, Mikkel Bak and Loft, Nikolai and Skov, Lone and Elberling, Jesper and Thomsen, Simon Francis and Alinaghi, Farzad},
  title = {Risk of Dyslipidemia Associated With Oral Janus Kinase Inhibitors: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {4},
  pages = {737--745},
  doi = {10.1111/ijd.70122}
}
Kostenlos starten →